PMID- 26136911
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 1792-0981 (Print)
IS  - 1792-1015 (Electronic)
IS  - 1792-0981 (Linking)
VI  - 9
IP  - 5
DP  - 2015 May
TI  - Clinical characteristics of a group of patients with multiple myeloma who had two 
      different lambda light chains by immunofixation electrophoresis: A retrospective study 
      from a single center.
PG  - 1895-1900
AB  - The objective of the present study was to conduct a retrospective analysis of the 
      clinical characteristics of a group of patients with multiple myeloma (MM) who 
      had two different immunoglobulin lambda light chains as determined by immunofixation 
      electrophoresis (IFE). A total of 26 patients with MM had two different lambda light 
      chains by IFE at diagnosis in hospital from January 2006 to June 2012. Data were 
      collected from the medical records of these patients. The clinical 
      characteristics, laboratory parameters, responses, risk factors and outcomes of 
      this special group of patients were retrospectively analyzed. The patients with 
      MM and two different lambda light chains by IFE accounted for 5.4% (26/483) of all the 
      patients with MM during the same period. There were 17 patients (65.4%) with 
      renal dysfunction and 10 patients (38.5%) with extramedullary plasmacytoma (EMP) 
      at diagnosis. Ten patients (38.5%) had abnormalities by fluorescence in situ 
      hybridization (FISH) including t(4;14), t(14;16) and/or del17p. Of these 
      patients, three (11.5%) achieved complete remission (CR), six (23.1%) very good 
      partial remission (VGPR), six (23.1%) partial remission (PR) and the overall 
      remission (OR) rate was 57.7% (15/26). The OR rate of the patients who received 
      chemotherapy with bortezomib was superior to that of the patients who received 
      chemotherapy without bortezomib (78.6% vs. 33.3%; P<0.05). The OR rate of the 
      patients who received autologous stem cell transplantation (SCT) was superior to 
      that of the patients who did not receive autologous SCT (77.8% vs. 47.1%; 
      P<0.05). The median overall survival (OS) was 12.6 months (range, 2-38 months) in 
      this study. The patients who received chemotherapy with bortezomib had a 
      significantly longer median OS as compared with the patients who received 
      chemotherapy without bortezomib (19 vs. 6 months; P=0.049). The patients who 
      received autologous SCT also had significantly longer median OS as compared with 
      the patients who did not receive autologous SCT (18 vs. 7 months; P=0.041). The 
      median duration of remission (DOR) was 5 months (range, 0-28 months). The 
      patients who received bortezomib or autologous SCT had significantly longer 
      median DOR than those who did not (P=0.046 and P=0.012, respectively). The 
      patients with abnormalities by FISH had similar OR rates, median OS and median 
      DOR as compared with the patients without abnormalities by FISH and there was no 
      statistically significant difference in OR rate, median OS and median DOR between 
      the patients with EMP and those without. The MM patients with two different lambda 
      light chains by IFE may have specific characteristics, and are accompanied by a 
      high incidence of renal dysfunction and EMP. They have a poor prognosis and 
      require novel therapy including bortezomib and autologous SCT.
FAU - Yang, Guangzhong
AU  - Yang G
AD  - Department of Hematology and Multiple Myeloma Research Center of Beijing, Beijing 
      Chaoyang Hospital, Capital Medical University, Beijing 100020, P.R. China.
FAU - Geng, Chuanying
AU  - Geng C
AD  - Department of Hematology and Multiple Myeloma Research Center of Beijing, Beijing 
      Chaoyang Hospital, Capital Medical University, Beijing 100020, P.R. China.
FAU - Chen, Wenming
AU  - Chen W
AD  - Department of Hematology and Multiple Myeloma Research Center of Beijing, Beijing 
      Chaoyang Hospital, Capital Medical University, Beijing 100020, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20150313
PL  - Greece
TA  - Exp Ther Med
JT  - Experimental and therapeutic medicine
JID - 101531947
PMC - PMC4471684
OTO - NOTNLM
OT  - multiple myeloma
OT  - prognosis
OT  - lambda light chain
EDAT- 2015/07/03 06:00
MHDA- 2015/07/03 06:01
PMCR- 2015/03/13
CRDT- 2015/07/03 06:00
PHST- 2014/04/07 00:00 [received]
PHST- 2015/02/13 00:00 [accepted]
PHST- 2015/07/03 06:00 [entrez]
PHST- 2015/07/03 06:00 [pubmed]
PHST- 2015/07/03 06:01 [medline]
PHST- 2015/03/13 00:00 [pmc-release]
AID - ETM-0-0-2352 [pii]
AID - 10.3892/etm.2015.2352 [doi]
PST - ppublish
SO  - Exp Ther Med. 2015 May;9(5):1895-1900. doi: 10.3892/etm.2015.2352. Epub 2015 Mar 
      13.